AVITA Medical, Inc.(RCEL)Earnings, Financials & Key RatiosAVITA Medical, Inc. (RCEL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current ratio of 0.47 and a negative equity position of $23.2M suggest an urgent need for external capital that poses a high risk of shareholder dilution.
AVITA Medical, Inc. (RCEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
AVITA Medical, Inc. (RCEL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.35vs $0.35+0.0% | $19Mvs $18M+5.2% |
| Q1 2026 | Feb 12, 2026 | $0.38vs $0.36-4.3% | $17Mvs $18M-2.3% |
| Q4 2025 | Nov 6, 2025 | $0.46vs $0.43-7.0% | $17Mvs $27M-36.5% |
| Q3 2025 | Aug 7, 2025 | $0.38vs $0.26-46.2% | $12Mvs $40M-70.1% |
Recent stock market news and headlines for AVITA Medical, Inc. (RCEL)
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells and improving operating room workflow RECELL GO is CE-marked in Europe and the U.K. and recently received regulatory authorization in Australia and New Zealand VALENCIA, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the presentation of new clinical data highlighting the first documented use of RECELL GO in the United Kingdom (U.K.) at the 2026 British Burn Association (BBA) Annual Meeting in Nottingham, U.K. The presentation, titled “First U.K. Clinical Experience of RECELL GO, an Automated Autologous Cell Harvesting Device, in Burn Surgery: A Case Series,” reports outcomes from 17 patients treated at Stoke Mandeville Hospital, one of the U.K.'s leading specialist burn units.
Key metrics vs top competitors for AVITA Medical, Inc. (RCEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.00 | $124.21M | -2.87 | 11.45% | -67.85% | — | — | |
| $0.42 | $58.84M | 13.98 | 14.21% | 1.5% | 3.68% | — | |
| $0.72 | $32.23M | -0.87 | 15.84% | -49.3% | -1344.47% | — | |
| $4.20 | $623.98M | 13.13 | 19.99% | 7.88% | 12.86% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $4.20 | $175.87M | -15.56 | 9.86% | -16.4% | -88.47% | — |
AVITA Medical, Inc. (RCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVITA Medical, Inc. (RCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 14, 2026·SEC
May 1, 2026·SEC
Feb 12, 2026·SEC
Get notified when RCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVITA Medical, Inc. (RCEL) stock FAQ — growth, dividends, profitability & financials explained
AVITA Medical, Inc. (RCEL) reported $72.3M in revenue for fiscal year 2025.
AVITA Medical, Inc. (RCEL) grew revenue by 11.5% over the past year. This is steady growth.
AVITA Medical, Inc. (RCEL) reported a net loss of $45.3M for fiscal year 2025.
AVITA Medical, Inc. (RCEL) had negative free cash flow of $30.7M in fiscal year 2025, likely due to heavy capital investments.
